TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26075381
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) and Acceptance and commitment therapy (ACT)
Study: 14749563
Drug: Oxandrolone (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone (0.1 mg/kg by mouth twice daily)
Study: 11273789
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg orally, twice daily)
Study: 9624308
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg sublingual melatonin
Study: 8895290
Drug: Droperidol 0.625
Normalized name: droPERidol 0.625 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.625 mg IV plus Metoclopramide 10 mg IV (Group DM)
Study: 25256137
Drug: MS-20 for
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS-20 for 1 week followed by 3 weeks of concomitant MS-20 plus chemotherapy
Study: 25256137
Drug: MS-20 treatment
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MS-20 treatment
Study: 25256137
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for 3 weeks
Study: 21095627
Drug: Oral ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ivabradine for 5 days prior to CTCA
Study: 21095627
Drug: Chronic beta-blockade
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic beta-blockade (atenolol 50mg twice a day for 5 days prior to CTCA)
Study: 18053198
Drug: Merional administered
Normalized name: Meriones unguiculatus skin
DrugBank: Meriones unguiculatus skin (DB10603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merional administered subcutaneously (s.c.)
Study: 18053198
Drug: Merional administered
Normalized name: Meriones unguiculatus skin
DrugBank: Meriones unguiculatus skin (DB10603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merional administered intramuscularly (i.m.)
Study: 8996744
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 450 mg clindamycin (CLDM) three times daily for 7 days
Study: 8996744
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of 2% CLDM phosphate in cream (self-made) 5 g once a day for 7 days
Study: 8996744
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 450 mg CLDM
Study: 8217999
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 50 mg/day (n = 103)
Study: 25057035
Drug: GnRH+ (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH+ (100 μg GnRH)
Study: 20395554
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment (n = 60)
Study: 7782725
Drug: Arabica oil
Normalized name: arabica coffee oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arabica oil (2 g per day)
Study: 7782725
Drug: Robusta oil
Normalized name: Shorea robusta resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robusta oil (2 g per day)
Study: 6414821
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg b.d. (oral)
Study: 6414821
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate 20 mg q.i.d. (inhalation)
Study: 31718678
Drug: Treat-to-target (T2T)
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treat-to-target (T2T) therapy aimed at DAS28-ESR remission
Study: 29268805
Drug: Reason for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reason for discontinuation of breast-feeding due to conflict stress
Study: 24476987
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine lozenge (4 mg) with expectancy
Study: 18198648
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SFI), antibiotics, and short-term pulse therapy with high efficient hormone
Study: 18198648
Drug: Antibiotics and
Normalized name: Antibiotics and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics and hormone pulse therapy
Study: 16402538
Drug: Oral pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pioglitazone (15 mg to 45 mg)
Study: 9502570
Drug: Glucose-charged dialysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-charged dialysate (9.17 mmol/l or 165 mg/dl)
Study: 10551383
Drug: Interferon-alpha treatment
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha treatment
Study: 2757899
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of cilazaprilat
Study: 25800548
Drug: ACE‐I/ARB treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE‐I/ARB treatment
Study: 7969680
Drug: Diuretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic treatment
Study: 18070786
Drug: Hyperbaric articaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric articaine 80 mg
Study: 19548294
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg daily
Study: 16960699
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg daily
Study: 14501737
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg daily
Study: 15647704
Drug: Cognitive‐behavioral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral therapy
Study: 9090340
Drug: Medication (fluoxetine)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (fluoxetine) plus psychological treatment
Study: 9090340
Drug: Supportive psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive psychotherapy plus medication
Study: 9090340
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus psychological treatment
Study: 31574303
Drug: Transcatheter mitral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter mitral valve repair (TMVr) plus maximally tolerated guideline-directed medical therapy (GDMT)
Study: 10559567
Drug: Denbufylline 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denbufylline 25, 50 or 100 mg
Study: 31532795
Drug: High-dose omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omega-3 fatty acids (O-3FA) for 6 months
Study: 19521272
Drug: Expectations of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectations of treatment (baseline expectations)
Study: 2453619
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy regimen (PVeBV)
Study: 2453619
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy regimen (PVeB)
Study: 29871240
Drug: Acoustic resonance
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acoustic resonance therapy combined with systemic steroid therapy and conventional drug therapy
Study: 29871240
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy and conventional drug therapy
Study: 25433294
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of real-time feedback and JIT CPR training
Study: 11580734
Drug: Gestational diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestational diabetes mellitus (GDM) treatment with low-caloric diet and insulin when appropriate
Study: 26682290
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream 3.75% applied once daily until complete clearance or a maximum of 8 weeks
Study: 26682290
Drug: Imiquimod cream
Normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imiquimod cream 2.5% applied once daily until complete clearance or a maximum of 8 weeks
Study: 22925000
Drug: Procalcitonin ultrasensitive-guided
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin ultrasensitive-guided antibiotic treatment
Study: 8987040
Drug: Atracurium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.5 mg/kg
Study: 7818124
Drug: Atracurium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium 0.3 mg/kg
Study: 23834406
Drug: CD only
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD only (nurse administered)
Study: 19060515
Drug: hylan G‐F
Approvals — FDA: no, EMA: no, PMDA: no
Description: hylan G‐F 20 (Synvisc), 2 ml, three intra-articular injections
Study: 19060515
Drug: sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium hyaluronate (Hyalgan), 2 ml, five intra-articular injections
Study: 19060515
Drug: No injections
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No injections (controls)
Study: 9141257
Drug: Aspirin 15
Normalized name: aspirin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 15 mg/kg
Study: 6690170
Drug: Oral nalbuphine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nalbuphine, 15 mg (N = 39)
Study: 6690170
Drug: Codeine, 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine, 60 mg (N = 42)
Study: 6690170
Drug: Oral nalbuphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nalbuphine (N = 39)
Study: 19228175
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active drugs
Study: 26350171
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of oral BP treatment for up to 10 years
Study: 26350171
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of intravenous BP treatment for up to 6 years
Study: 22252366
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vitamin E in crude soybean oil diet
Study: 22252366
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vitamin E in crude soybean oil diet
Study: 22252366
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg vitamin E in acidulated soybean oil soapstock diet
Study: 9284856
Drug: Troglitazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troglitazone (200 mg/day)
Study: 3541426
Drug: ID-1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID-1 group (3 doses of 0.1 ml intradermally at 0, 1 month, and 4 months)
Study: 3541426
Drug: ID-2 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: ID-2 group (2 doses of 0.2 ml intradermally at 0 and 1 dose of 0.1 ml at 4 months)
Study: 10958810
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation at 15 mg (RDA)
Study: 8898643
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg/4 h)
Study: 8898643
Drug: Somatostatin (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (continuous infusion of 250 micrograms/h after an intravenous injection of 250 micrograms)
Study: 31303706
Drug: Palonosetron (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (1 mcg/kg, max 75 mcg)
Study: 31303706
Drug: Ondansetron (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.1 mg/kg, max 8 mg)
Study: 16846342
Drug: beta‐TCP +
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta‐TCP + 1.0 mg/mL of recombinant human PDGF‐BB (rhPDGF‐BB)
Study: 2579938
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy following irradiation
Study: 28335729
Drug: 5 weeks
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 weeks of training with an oral screen for neuromuscular training focused on orofacial and pharyngeal muscles
Study: 25774595
Drug: Risk model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk model association with response to therapy, overall and GVHD-specific survival and non-relapse mortality
Study: 19374150
Drug: Healthy older
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy older adults swallowing various bolus types (5 or 10 mL)
Study: 17988533
Drug: Oxymatrine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine (600 mg, intravenous drip, once a day for 7 days)
Study: 17988533
Drug: Traditional equilibrium
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional equilibrium salt treatment (control group)
Study: 9400460
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (10 ml)
Study: 138557
Drug: 0.025% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% betamethasone benzoate gel
Study: 3582724
Drug: 0.1% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% betamethasone valerate cream
Study: 22669627
Drug: Po-husk (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Po-husk (14 g/day)
Study: 22669627
Drug: Placebo (microcrystalline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (microcrystalline cellulose 14 g/day)
Study: 28166613
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs (methotrexate, cyclosporin)
Study: 16133653
Drug: Combined weight-bearing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined weight-bearing training program (50 min, twice a week)
Study: 26163609
Drug: Tailored triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored triple therapy with placebo (esomeprazole 20 mg bid, clarithromycin 500 mg bid or metronidazole 400 mg tid if clarithromycin resistance and amoxicillin 1000 mg bid)
Study: 26163609
Drug: Tailored triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored triple therapy plus pretreatment with probiotic containing yogurt
Study: 14520776
Drug: Tooth whitening
Normalized name: CAMPHOR, (-)- 1 g in 24 g TOPICAL PATCH [Tooth Whitening Strip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth whitening gel containing 25% carbamide peroxide
Study: 14520776
Drug: Tooth whitening
Normalized name: CAMPHOR, (-)- 1 g in 24 g TOPICAL PATCH [Tooth Whitening Strip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth whitening gel containing 8.7% hydrogen peroxide
Study: 19820754
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor + Angiotensin receptor blocker (lisinopril 10 mg/day + candesartan 16 mg/day)
Study: 19820754
Drug: Aldosterone antagonist
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone antagonist (eplerenone 25 mg/day)
Study: 19820754
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (lisinopril 20 mg/day)
Study: 11077029
Drug: Rifampicin 1200
Normalized name: Rifampicine
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 1200 mg/day in two divided doses
Study: 9217894
Drug: Insulin with
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin with L-NMMA (30 micrograms/kg/min)
Study: 9217894
Drug: Insulin with
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin with propranolol (0.2 microgram/kg/min)
Study: 9217894
Drug: L-NMMA (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (30 micrograms/kg/min) alone
Study: 775954
Drug: Intravenous digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous digoxin
Study: 27770820
Drug: Contingency Management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contingency Management (CM) intervention with 12 once-weekly sessions and voucher rewards for cannabis-free urinalysis
Study: 27770820
Drug: Optimised Treatment
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised Treatment as Usual (OTAU) psychoeducational package
Study: 23905488
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (50 mg daily for 12 weeks)
Study: 23905488
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (600 mg parenterally for 7 days, followed by 600 mg orally for 12 weeks)
Study: 23905488
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Transdermal testosterone and Alpha-lipoic acid)
Study: 21090960
Drug: SADV (coordinated
Approvals — FDA: no, EMA: no, PMDA: no
Description: SADV (coordinated substance abuse and domestic violence treatment program)
Study: 17029131
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine (single dose)
Study: 8561324
Drug: IV clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV clonidine treatment
Study: 30203386
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg for 5 days
Study: 30203386
Drug: Baloxavir marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil 40 mg with oseltamivir 75 mg for 5 days
Study: 23244155
Drug: Psychoeducational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational program (eight 90 minute weekly sessions)
Study: 7008062
Drug: Vehicle infusion
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle infusion (control)
Study: 2752040
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment (325 mg/d)
Study: 616222
Drug: lynestrenol 0.5
Normalized name: lynestrenol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lynestrenol 0.5 mg
Study: 616222
Drug: lynestrenol 0.5
Normalized name: lynestrenol 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lynestrenol 0.5 mg + ethinyl estradiol 0.05 mg
Study: 616222
Drug: d‐norgestrel 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐norgestrel 0.25 mg + ethinyl estradiol 0.05 mg
Study: 23030716
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg/day) for 6 weeks before surgery
Study: 26093811
Drug: Denosumab 120
Normalized name: DENOSUMAB 120 MG/1.7 ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 120 mg
Study: 26093811
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 4 mg
Study: 17190950
Drug: Immediate antiepileptic
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate antiepileptic treatment
Study: 21531706
Drug: Treatment only
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment only in the event of seizure recurrence
Study: 3545246
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with codeine (300-600 mg with 30-60 mg codeine) and placebo TENS
Study: 2571492
Drug: Lefetamine administered
Normalized name: amfetamine
DrugBank: Amphetamine (DB00182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lefetamine administered to opiate addicts with acute withdrawal syndrome
Study: 10321522
Drug: PUVA-cream therapy
Normalized name: dimethicone Topical Cream [Mederma Stretch Mark Therapy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA-cream therapy
Study: 1926059
Drug: Dermatan sulfate
Normalized name: dermatan sulfate
DrugBank: Dermatan sulfate (DB15880)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermatan sulfate (DS) 400 mg
Study: 1926059
Drug: Heparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5,000 IU
Study: 6760652
Drug: Natamycin vaginal
Normalized name: Natamycin
DrugBank: Natamycin (DB00826)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Natamycin vaginal tablets for 10 days, partners treated with natamycin cream
Study: 6760652
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream for partners
Study: 28215166
Drug: Current anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current anti-inflammatory drugs
Study: 25956843
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (L‐AmB) inhalation
Study: 25956843
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no L‐AmB inhalation)
Study: 16467677
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin 0.5% (1 drop every 15 minutes for a total of 3 doses starting 1 hour before surgery)
Study: 16467677
Drug: Topical moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical moxifloxacin 0.5% (self-administered 4 times daily for 3 days before surgery and at 7 am on the day of surgery)
Study: 16467677
Drug: Topical gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gatifloxacin 0.3% (1 drop every 15 minutes for a total of 3 doses starting 1 hour before surgery)
Study: 16467677
Drug: Topical gatifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gatifloxacin 0.3% (self-administered 4 times daily for 3 days before surgery and at 7 am on the day of surgery)